Aflibercept Biosimilar(Rophibio)

N/A

Report date: 2024/07/31 15:37:58

Base Information

Drug NameAflibercept Biosimilar(Rophibio)

Drug Alias NameRBS-001

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein

Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors

TargetsPlacental Growth FactorVascular endothelial growth factor A

Therapy Area/IndicationsWet age-related macular degenerationMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesRophibio Inc

China Registration ClassN/A

Active CompaniesRophibio Inc

Inactive CompaniesN/A

Active IndicationsWet age-related macular degenerationMacular Degeneration

Inactive IndicationsN/A

ATC CodeL01XX44S01LA05